Dallas, TX -- (SBWIRE) -- 06/15/2015 -- The report "Chlamydia Infections - Pipeline Review, H1 2015" provides an overview of the Chlamydia Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Complete report on Anesthetic Effect with 26 market data tables and 14 figures, spread across 85 pages is available at http://www.rnrmarketresearch.com/chlamydia-infections-pipeline-review-h1-2015-market-report.html .

Companies discussed in this Chlamydia Infections – Pipeline Review, H1 2015 report include Abera Bioscience AB, Adamis Pharmaceuticals Corporation, Big DNA Ltd., CEL-SCI Corporation, Foamix Pharmaceuticals Ltd., Genocea Biosciences, Inc., Merck & Co., Inc., Osel Inc., Prokarium Ltd., QureTech Bio AB.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are Ab-03, acALY-18, BDNA-003, Biologic for Infectious Disease, C-31G, CEL-1000, chlamydia trachomatis vaccine, chlamydia vaccine, Drugs to Block Virulence for Chlamydia Infections, GEN-001, minocycline Gel, Peptides to Inhibit CPAF for Chlamydia Infections, Small Molecules for Chlamydophila Infections, Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections, solithromycin, VNI-201.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=390971
(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases Cover by this report includes:

-Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

-Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria

-Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications

-Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center

-Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified

Inquire for Disocunt @ http://www.rnrmarketresearch.com/contacts/discount?rname=390971
(This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Chlamydia Infections, H1 2015 9
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2015 18
Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 19
Chlamydia Infections - Pipeline by Big DNA Ltd., H1 2015 20
Chlamydia Infections - Pipeline by CEL-SCI Corporation, H1 2015 21
Chlamydia Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 22
Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H1 2015 23
Chlamydia Infections - Pipeline by Merck & Co., Inc., H1 2015 24
Chlamydia Infections - Pipeline by Osel Inc., H1 2015 25
Chlamydia Infections - Pipeline by Prokarium Ltd., H1 2015 26
Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Stage and Target, H1 2015 30
Number of Products by Stage and Mechanism of Action, H1 2015 32
Number of Products by Stage and Route of Administration, H1 2015 34
Number of Products by Stage and Molecule Type, H1 2015 36
Chlamydia Infections Therapeutics - Recent Pipeline Updates, H1 2015 61
Chlamydia Infections - Dormant Projects, H1 2015 70

List of Figures
Number of Products under Development for Chlamydia Infections, H1 2015 9
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Top 10 Targets, H1 2015 29
Number of Products by Stage and Top 10 Targets, H1 2015 30
Number of Products by Top 10 Mechanism of Actions, H1 2015 31
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32
Number of Products by Top 10 Routes of Administration, H1 2015 33
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34
Number of Products by Top 10 Molecule Types, H1 2015 35
Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Explore more reports on Anesthesia Drugs at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/anesthesia-drugs

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.